Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

10.71
-0.0950-0.88%
Post-market: 10.960.2500+2.33%19:30 EDT
Volume:1.87M
Turnover:20.11M
Market Cap:950.77M
PE:-3.18
High:10.95
Open:10.90
Low:10.61
Close:10.81
52wk High:13.90
52wk Low:7.36
Shares:88.77M
Float Shares:70.60M
Volume Ratio:1.01
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3668
EPS(LYR):-3.1784
ROE:-167.71%
ROA:-31.30%
PB:19.63
PE(LYR):-3.37

Loading ...

Kura Oncology Earnings Call Signals Early Launch Strength

TIPRANKS
·
May 20

Kura Oncology joins TD Cowen Oncology Innovation Summit fireside chat

Reuters
·
May 20

Kura Oncology (KURA) Receives a Buy from LifeSci Capital

TIPRANKS
·
May 16

Kura Oncology (KURA) Q1 Loss Of US$73 Million Reinforces Bearish Profitability Concerns

Simply Wall St.
·
May 14

Lake Street Remains a Buy on Kura Oncology (KURA)

TIPRANKS
·
May 13

Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Maze Therapeutics, Inc. (MAZE)

TIPRANKS
·
May 13

Kura Oncology reports Q1 EPS (83c), consensus (78c)

TIPRANKS
·
May 13

Kura Oncology Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Kura Oncology Q1 Loss Widens, Revenue Rises

MT Newswires Live
·
May 13

Kura Oncology posts corporate presentation on KOMZIFTI launch and ziftomenib development strategy

Reuters
·
May 13

Earnings Flash (KURA) Kura Oncology Posts Q1 Per Share Loss $0.83, vs. FactSet Est of $0.83 Loss

MT Newswires Live
·
May 13

Kura Oncology Q1 FY26 net loss widens to $73.3 million; revenue rises to $18.3 million

Reuters
·
May 13

Kura Oncology Q1 EPS $(0.83) Beats $(0.94) Estimate, Sales $18.265M Miss $18.513M Estimate

Benzinga Earnings
·
May 13

Kura Oncology Q1 EPS USD -0.83

THOMSON REUTERS
·
May 13

Kura Oncology Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 13

U.S. Earnings Preview: After Market Close May 12

Dow Jones
·
May 13

Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial

TIPRANKS
·
May 13

Kura updates ziftomenib-plus-7+3 trial data in frontline AML at EHA 2026

Reuters
·
May 12

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

GlobeNewswire
·
May 12

Kura Oncology Inc expected to post a loss of 63 cents a share - Earnings Preview

Reuters
·
May 09